BioPharma Resources

Investigational drug · Phase 3

CYB003

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

5

Any phase or sponsor naming "CYB003"

First trial start

2024

Dec 17, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CYB003", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Major Depressive Disorder
  • Major Depressive Disorder (MDD)
  • Depression in Adults
  • Depression - Major Depressive Disorder
  • Depression Disorders
  • Depression Disorder
  • Depression

Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry

Largest trials

Live from ClinicalTrials.gov: studies naming "CYB003" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Major Depressive Disorder

  • BrenipatideLY3537031Phase 313 trials

    Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major

  • AzetukalnerXEN1101Phase 39 trials

    Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder

  • SEP-363856UlotarontPhase 37 trials

    Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder

  • BHV-7000Phase 36 trials

    Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder

  • NBI-1065845TAK-653, OsavampatorPhase 35 trials

    Neurocrine Biosciences · Major Depressive Disorder

  • CYM-53093Navacaprant, NMRA-335140Phase 34 trials

    Neumora Therapeutics, Inc. · Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder

  • DT120MM120, lysergide tartratePhase 34 trials

    Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder

  • PsilocybinCOMP360Phase 34 trials

    COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.